Cargando…

A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma

BACKGROUNDS: Osteosarcoma (OS) is easy to metastasis. Necroptosis-related long noncoding RNA (lncRNA) (NRlncRNA) plays a vital role in the tumorigenesis of many malignant tumors. Nonetheless, there have been few studies investigating the relations between NRlncRNA and OS. During the investigation, N...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yixin, Xu, Jie, Lin, Jiexiang, Lin, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283071/
https://www.ncbi.nlm.nih.gov/pubmed/35844445
http://dx.doi.org/10.1155/2022/8003525
_version_ 1784747254722068480
author Zheng, Yixin
Xu, Jie
Lin, Jiexiang
Lin, Yuan
author_facet Zheng, Yixin
Xu, Jie
Lin, Jiexiang
Lin, Yuan
author_sort Zheng, Yixin
collection PubMed
description BACKGROUNDS: Osteosarcoma (OS) is easy to metastasis. Necroptosis-related long noncoding RNA (lncRNA) (NRlncRNA) plays a vital role in the tumorigenesis of many malignant tumors. Nonetheless, there have been few studies investigating the relations between NRlncRNA and OS. During the investigation, NRlncRNAs in OS were confirmed and characterized and their relationships with prognoses were investigated. METHODS: NRlncRNAs were downloaded from The Cancer Genome Atlas (TCGA) OS expression data and clinical-pathological information. First, univariate Cox regression and LASSO regression analyses were used to screen for prognostic-related NRlncRNAs. Second, multivariate regression analyses were used to establish a prognostic nomogram for predicting individual survival probability. Survival analyses demonstrated that high-risk patients (HRPs) had a poor prognosis. In addition, gene set enrichment analyses (GSEA) were used to identify gene function in high- and low-risk groups based on the survival mode. RESULTS: The 7 NRlncRNAs (AC004812.2, AC022915.1, AC073073.2, AC090559.1, AL512330.1, DDN-AS1, and SENCR) were shown to have a distinct difference and were used to construct an NRlncRNA signature. Using the signature as a risk score was an independent factor for OS patients. The signature divided OS patients into the high- and low-risk groups. Furthermore, the seven lncRNAs were significantly enriched in cell migration and metabolism. CONCLUSIONS: The 7 NRlncRNA survival models have the potential to serve as therapeutic targets and molecular biomarkers for patients with OS, as well as to precisely predict OS prognoses.
format Online
Article
Text
id pubmed-9283071
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92830712022-07-15 A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma Zheng, Yixin Xu, Jie Lin, Jiexiang Lin, Yuan Comput Math Methods Med Research Article BACKGROUNDS: Osteosarcoma (OS) is easy to metastasis. Necroptosis-related long noncoding RNA (lncRNA) (NRlncRNA) plays a vital role in the tumorigenesis of many malignant tumors. Nonetheless, there have been few studies investigating the relations between NRlncRNA and OS. During the investigation, NRlncRNAs in OS were confirmed and characterized and their relationships with prognoses were investigated. METHODS: NRlncRNAs were downloaded from The Cancer Genome Atlas (TCGA) OS expression data and clinical-pathological information. First, univariate Cox regression and LASSO regression analyses were used to screen for prognostic-related NRlncRNAs. Second, multivariate regression analyses were used to establish a prognostic nomogram for predicting individual survival probability. Survival analyses demonstrated that high-risk patients (HRPs) had a poor prognosis. In addition, gene set enrichment analyses (GSEA) were used to identify gene function in high- and low-risk groups based on the survival mode. RESULTS: The 7 NRlncRNAs (AC004812.2, AC022915.1, AC073073.2, AC090559.1, AL512330.1, DDN-AS1, and SENCR) were shown to have a distinct difference and were used to construct an NRlncRNA signature. Using the signature as a risk score was an independent factor for OS patients. The signature divided OS patients into the high- and low-risk groups. Furthermore, the seven lncRNAs were significantly enriched in cell migration and metabolism. CONCLUSIONS: The 7 NRlncRNA survival models have the potential to serve as therapeutic targets and molecular biomarkers for patients with OS, as well as to precisely predict OS prognoses. Hindawi 2022-07-07 /pmc/articles/PMC9283071/ /pubmed/35844445 http://dx.doi.org/10.1155/2022/8003525 Text en Copyright © 2022 Yixin Zheng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zheng, Yixin
Xu, Jie
Lin, Jiexiang
Lin, Yuan
A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title_full A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title_fullStr A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title_full_unstemmed A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title_short A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma
title_sort novel necroptosis-related lncrna signature for osteosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283071/
https://www.ncbi.nlm.nih.gov/pubmed/35844445
http://dx.doi.org/10.1155/2022/8003525
work_keys_str_mv AT zhengyixin anovelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT xujie anovelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT linjiexiang anovelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT linyuan anovelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT zhengyixin novelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT xujie novelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT linjiexiang novelnecroptosisrelatedlncrnasignatureforosteosarcoma
AT linyuan novelnecroptosisrelatedlncrnasignatureforosteosarcoma